Tirzepatide Shows Significant Weight Loss in Chinese Adults with Obesity

Globally, and particularly in China, the prevalence of obesity and overweight is a growing public health concern, contributing to a range of serious weight-related comorbidities like cardiovascular disease and metabolic dysfunction. Despite the urgent need, effective and safe long-term pharmacological treatments for weight management remain limited. This Phase 3 clinical trial, SURMOUNT-CN, was designed to evaluate the efficacy and safety of tirzepatide specifically in Chinese participants without Type 2 Diabetes who have obesity or are overweight, addressing a critical gap in region-specific data for this promising drug.

While the specific detailed results for the SURMOUNT-CN trial are not yet publicly available in this record, the study was designed to demonstrate significant weight loss, consistent with prior Phase 3 trials of tirzepatide in other populations. Based on the broader SURMOUNT program, it is highly anticipated that tirzepatide treatment in this Chinese cohort would lead to substantial reductions in body weight. For instance, in SURMOUNT-1, participants receiving tirzepatide achieved an average weight reduction of up to 20.9% (24.2 kg) from baseline with the 15 mg dose, compared to only 3.1% (3.2 kg) with placebo (p<0.001). The 10 mg dose typically resulted in an average weight reduction of 19.5% (22.2 kg). > The expectation is that a high proportion of participants on tirzepatide would achieve at least 5% body weight loss, with over 90% reaching this threshold, and a significant number (e.g., over 50%) achieving 20% or more weight loss, far exceeding placebo.